I think of all the draft releases BMY did for the ipi decision, the one they didn't do was a broad label one. Probably took them half the night to weed out phrases from the rushed rewrite. Rumors (!) are these edits resulted in last minute deletions of:
"BMY executives were high-fivin' and slappin' some ass upon reading the FDA announcement."
"BMY executives originally promised to shred the compromising pictures of Richard Pazdur, head of the FDA's oncology division, but reconsidered in light of the obvious success of this aspect of their regualtory strategy."
"BMY executives immediately phoned their mistresses (boytoys) and told them to go shopping for something skimpy because 'Daddy (Mommy) is going to get a honkin' bonus for this one.'"
"To prevent confusion among melanoma patients, BMY clarified that they would not be accepting body parts -- particularly, but not limited to, arms and legs -- as partial or complete payment for Yervoy's $120,000 price."
PR is complicated and takes some time to get right, you know...
Unless otherwise indicated, this is the personal viewpoint of David
Miller and not necessarily that of Biotech Stock Research, LLC.
We're on Twitter at BiotechStockRsr
